Millennium Management
SPRY icon

Millennium Management’s ARS Pharmaceuticals SPRY Stock Holding History

Millennium Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-53,900
Closed -$204K – 6509
2023
Q3 		$204K Sell
53,900
-21,100
-28% -$139K ﹤0.01% 5121
2023
Q2 		$503K Buy
+75,000
New +$501K ﹤0.01% 4541

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $921M AUM 60.37% 1-Year Est. Return

Millennium Management's SPRY Position: Q1 2026 in Review

Millennium Management increased its ARS Pharmaceuticals (SPRY) stake by 89% in Q1 2026, buying an estimated $27M and bringing the position to 5,982,919 shares worth $48M. The position accounts for 0.02% of the portfolio, ranked #855.

Millennium Management first reported a position in SPRY in Q4 2020 and has held it in 17 quarters since. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Millennium Management held 5,982,919 shares of ARS Pharmaceuticals worth $48M as of Q1 2026.
  • Millennium Management bought 2,814,513 ARS Pharmaceuticals shares in Q1 2026, an estimated $27M.
  • ARS Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #855 holding.
  • Millennium Management first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.